These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

153 related articles for article (PubMed ID: 84209)

  • 81. Comparative immunogenicity of Haemophilus influenzae type b polysaccharide-protein conjugate vaccines.
    Granoff DM; Holmes SJ
    Vaccine; 1991 Jun; 9 Suppl():S30-4; discussion S42-3. PubMed ID: 1891954
    [TBL] [Abstract][Full Text] [Related]  

  • 82. Dose-related immunogenicity of Haemophilus influenzae type b capsular polysaccharide-Neisseria meningitidis outer membrane protein conjugate vaccine.
    Wong VK; Quagliata R; Adler R; Kim KS
    Am J Dis Child; 1991 Jul; 145(7):742-5. PubMed ID: 2058604
    [TBL] [Abstract][Full Text] [Related]  

  • 83. An enzyme-linked immunosorbent assay for quantitation of Haemophilus Influenzae type b polysaccharide-specific IgG1 and IgG2 in human and infant rhesus monkey sera.
    Dolan KT; Staub JM; Schofield TL; Ahonkhai VI; Ellis RW; Vella PP
    J Immunoassay; 1991; 12(4):543-64. PubMed ID: 1806588
    [TBL] [Abstract][Full Text] [Related]  

  • 84. Haemophilus influenzae type b conjugate vaccine (meningococcal protein conjugate): immunogenicity and safety at various doses.
    Yogev R; Arditi M; Chadwick EG; Amer MD; Sroka PA
    Pediatrics; 1990 Apr; 85(4 Pt 2):690-3. PubMed ID: 2107520
    [TBL] [Abstract][Full Text] [Related]  

  • 85. Immunization of humans with polysaccharide vaccines induces systemic, predominantly polymeric IgA2-subclass antibody responses.
    Tarkowski A; Lue C; Moldoveanu Z; Kiyono H; McGhee JR; Mestecky J
    J Immunol; 1990 May; 144(10):3770-8. PubMed ID: 2110213
    [TBL] [Abstract][Full Text] [Related]  

  • 86. Serum opsonic activity after immunization of adults with Haemophilus influenzae type b-diphtheria toxoid conjugate vaccine.
    Cates KL; Marsh KH; Granoff DM
    Infect Immun; 1985 Apr; 48(1):183-9. PubMed ID: 3872263
    [TBL] [Abstract][Full Text] [Related]  

  • 87. Immunization with Haemophilus influenzae type b polysaccharide vaccine at 18 and 24 months of age: evidence of decreased immunogenicity.
    Adderson EE; Chisholm N; Halperin SA
    Clin Invest Med; 1991 Aug; 14(4):338-45. PubMed ID: 1782732
    [TBL] [Abstract][Full Text] [Related]  

  • 88. Anti-polyribosyl-ribitol phosphate and anti-N. meningitidis outer membrane protein antibody levels following PRP-OMP conjugate vaccination.
    Wong VK; Kim KS
    Vaccine; 1993; 11(9):979-80. PubMed ID: 8212847
    [No Abstract]   [Full Text] [Related]  

  • 89. Response of 7- to 15-month-old infants to sequential immunization with Haemophilus influenzae type b-CRM197 conjugate and polysaccharide vaccines.
    Rothstein EP; Schiller RP; Girone JA; Hipp TJ; Souder RL; Bernstein HH; Madore DV; Johnson CL; Smith DH
    Am J Dis Child; 1991 Aug; 145(8):898-900. PubMed ID: 1858727
    [TBL] [Abstract][Full Text] [Related]  

  • 90. Elevated levels of maternal anti-tetanus toxin antibodies do not suppress the immune response to a Haemophilus influenzae type b polyribosylphosphate-tetanus toxoid conjugate vaccine.
    Panpitpat C; Thisyakorn U; Chotpitayasunondh T; Fürer E; Que JU; Hasler T; Cryz SJ
    Bull World Health Organ; 2000; 78(3):364-71. PubMed ID: 10812736
    [TBL] [Abstract][Full Text] [Related]  

  • 91. Comparison of naturally acquired and vaccine-induced antibodies to Haemophilus influenzae type b capsular polysaccharide.
    Jelonek MT; Chang SJ; Chiu CY; Park MK; Nahm MH; Ward JI
    Infect Immun; 1993 Dec; 61(12):5345-50. PubMed ID: 8225608
    [TBL] [Abstract][Full Text] [Related]  

  • 92. Clinical experience with Haemophilus influenzae type b conjugate vaccines.
    Mäkelä PH; Eskola J; Peltola H; Takala AK; Käyhty H
    Pediatrics; 1990 Apr; 85(4 Pt 2):651-3. PubMed ID: 2179855
    [TBL] [Abstract][Full Text] [Related]  

  • 93. Immunization response varies with intensity of acute lymphoblastic leukemia therapy.
    Ridgway D; Wolff LJ; Deforest A
    Am J Dis Child; 1991 Aug; 145(8):887-91. PubMed ID: 1858726
    [TBL] [Abstract][Full Text] [Related]  

  • 94. Clinical efficacy of meningococcus group A capsular polysaccharide vaccine in children three months to five years of age.
    Peltola H; Mäkelä H; Käyhty H; Jousimies H; Herva E; Hällström K; Sivonen A; Renkonen OV; Pettay O; Karanko V; Ahvonen P; Sarna S
    N Engl J Med; 1977 Sep; 297(13):686-91. PubMed ID: 408682
    [TBL] [Abstract][Full Text] [Related]  

  • 95. Limited efficacy of a Haemophilus influenzae type b conjugate vaccine in Alaska Native infants. The Alaska H. influenzae Vaccine Study Group.
    Ward J; Brenneman G; Letson GW; Heyward WL
    N Engl J Med; 1990 Nov; 323(20):1393-401. PubMed ID: 2233906
    [TBL] [Abstract][Full Text] [Related]  

  • 96. IgG subclass response to immunization with Haemophilus influenzae type b polysaccharide-outer membrane protein conjugate vaccine.
    Granoff DM; Weinberg GA; Shackelford PG
    Pediatr Res; 1988 Aug; 24(2):180-5. PubMed ID: 3263612
    [TBL] [Abstract][Full Text] [Related]  

  • 97. Persistence of serum antibodies elicited by Haemophilus influenzae type b-tetanus toxoid conjugate vaccine in infants vaccinated at 3, 5 and 12 months of age.
    Claesson BA; Schneerson R; Lagergård T; Trollfors B; Taranger J; Johansson J; Bryla D; Robbins JB
    Pediatr Infect Dis J; 1991 Aug; 10(8):560-4. PubMed ID: 1891286
    [TBL] [Abstract][Full Text] [Related]  

  • 98. Differing serologic responses to an haemophilus influenzae type b polysaccharide-neisseria meningitidis outer membrane protein conjugate (PRP-OMPC) vaccine in australian aboriginal and caucasian infants - implications for disease epidemiology.
    Guthridge S; McIntyre P; Isaacs D; Hanlon M; Patel M
    Vaccine; 2000 May; 18(23):2584-91. PubMed ID: 10775792
    [TBL] [Abstract][Full Text] [Related]  

  • 99. Haemophilus influenzae type b immunization in infants in the United Kingdom: effects of diphtheria/tetanus/acellular pertussis/Hib combination vaccine, significant prematurity, and a fourth dose.
    Berrington JE; Cant AJ; Matthews JN; O'Keeffe M; Spickett GP; Fenton AC
    Pediatrics; 2006 Apr; 117(4):e717-24. PubMed ID: 16549502
    [TBL] [Abstract][Full Text] [Related]  

  • 100. The immunogenicity of Hemophilus influenzae type B polysaccharide-Neisseria meningitidis group B outer membrane protein complex vaccine in infants and young children.
    Shapiro ED; Capobianco LA; Berg AT; Zitt MQ
    J Infect Dis; 1989 Dec; 160(6):1064-7. PubMed ID: 2511254
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.